公开(公告)号：US20240279305A1

公开(公告)日：2024-08-22

申请号：US18637627

申请日：2024-04-17

Applicant: Alector LLC

Inventor： Spencer Liang ,  Samuel Nalle ,  Jeonghoon Sun ,  Rashmi Bankoti ,  Hua Long

IPC: C07K14/705 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  A61P35/04 ,  C07K16/28

CPC classification number: C07K14/70503 ,  A61K38/1774 ,  A61K45/06 ,  A61P35/00 ,  A61P35/04 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/545 ,  C07K2317/76 ,  C07K2319/30

Abstract: The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.

公开(公告)号：US12060422B2

公开(公告)日：2024-08-13

申请号：US17256508

申请日：2019-06-28

Applicant: Alector LLC

Inventor： Andrew Pincetic ,  Patricia Culp ,  Arnon Rosenthal

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/75 ,  C07K2317/92

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPβ1 polypeptide, e.g., a human SIRPβ1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20240254227A1

公开(公告)日：2024-08-01

申请号：US18637960

申请日：2024-04-17

Applicant: Alector LLC

Inventor： Sarah Emily Headland ,  Ilaria Tassi ,  Chenyu A. Lee ,  Earl Kim ,  Adiljan Ibrahim ,  Marina Roell ,  Angie Grace Yee

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/92

Abstract: The present disclosure is generally directed to antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD300LB polypeptide, e.g., a mammalian CD300LB or human CD300LB, and use of such compositions in preventing, reducing risk, or treating a disease or disorder an individual in need thereof.

公开(公告)号：US20240166738A1

公开(公告)日：2024-05-23

申请号：US18551963

申请日：2022-03-23

Applicant: ALECTOR LLC

Inventor： Herve RHINN ,  Eric BROWN

IPC: C07K16/28 ,  A61P31/14

CPC classification number: C07K16/28 ,  A61P31/14

Abstract: The present disclosure is generally directed to uses of antibodies that bind to a TMEM106B protein in treating, preventing, or reducing the risk of coronavirus (e.g., SARS-COV-2) infection.

公开(公告)号：US20240076362A1

公开(公告)日：2024-03-07

申请号：US18310207

申请日：2023-05-01

Applicant: Alector LLC

Inventor： Jeonghoon SUN ,  Wei-Hsien HO ,  Muhammad A. ALHAWAGRI ,  Philip Ling KONG ,  Herve RHINN ,  Hua LONG ,  Karpagam SRINIVASAN ,  Ananya MITRA ,  Daniel P. BERMINGHAM ,  Klaus-Dieter HEGER ,  Santiago Viveros SALAZAR ,  Francesca CIGNARELLA ,  Ilaria TASSI ,  Tina SCHWABE ,  Angie Grace YEE ,  Arnon ROSENTHAL

IPC: C07K16/18

CPC classification number: C07K16/18 ,  A61K2039/505

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230159637A1

公开(公告)日：2023-05-25

申请号：US17801776

申请日：2021-02-23

Applicant: Alector LLC ,  Washington University

Inventor： Francesca CIGNARELLA ,  Fabia FILIPELLO ,  Bryan BOLLMAN ,  Arnon ROSENTHAL ,  Tina SCHWABE ,  Ilaria TASSI ,  Laura PICCIO

IPC: C07K16/28 ,  A61P25/28

CPC classification number: C07K16/2803 ,  A61P25/28 ,  A61K2039/505

Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.

公开(公告)号：US20220380455A1

公开(公告)日：2022-12-01

申请号：US17722624

申请日：2022-04-18

Applicant: Alector LLC

Inventor： Philip KONG ,  Herve RHINN ,  Tina SCHWABE ,  Angie YEE ,  Arnon ROSENTHAL

IPC: C07K16/28 ,  A61P25/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, anti-body fragments, etc., that specifically bind a MS4A6A polypeptide, e g., a mammalian MS4A6A or human MS4A6A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US11472874B2

公开(公告)日：2022-10-18

申请号：US16965676

申请日：2019-01-31

Applicant: Alector LLC

Inventor： Philip Kong ,  Herve Rhinn ,  Tina Schwabe ,  Angie Yee ,  Ilaria Tassi ,  Muhammad Abbas Alhawagri ,  Arnon Rosenthal

IPC: C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US11470827B2

公开(公告)日：2022-10-18

申请号：US16218299

申请日：2018-12-12

Applicant: Alector LLC

Inventor： Ilaria Tassi ,  Asa Abeliovich ,  Seung-Joo Lee ,  Arnon Rosenthal ,  Tina Schwabe

IPC: A01K67/027 ,  C07H21/04 ,  C07K14/705 ,  A61K49/00

Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from TREM1, TREML1, TREM2, TREML2, and TREML4, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human TREM immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human TREM repertoire.

公开(公告)号：US11440957B2

公开(公告)日：2022-09-13

申请号：US16959081

申请日：2018-12-21

Applicant: ALECTOR LLC

Inventor： Arnon Rosenthal ,  Eric Brown ,  Tina Schwabe ,  Angie Yee ,  Herve Rhinn

IPC: C07K16/18 ,  C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.